A hybrid of disposable and stainless steel systems will remain the biomanufacturing model for the near future, says Pall reporting a robust first quarter 2015.
Single-use continues to be adopted by the bioprocessing industry, but drugmakers are still hesitant to use disposable chromatography systems, says EMD Millipore.
Turkey’s efforts to increase local biopharmaceutical production have prompted GE Healthcare Life Sciences to set up a biopharmaceutical technology training centre in Istanbul.
The products, unveiled at BioProcess International in Boston this week, will help industry with their upstream and downstream processing and include an anti-CHO host cell protein detection kit, the first single-use fermentor, and a new mammalian expression...
US academics have licensed a mobile clean room design from Xoma for a vaccine and medical countermeasure plant being built in Texas as part of an HHS-funded project.
GlaxoSmithKline will not restart production at a vaccine plant in Belgium until an independent investigation determines how liquid contaminated with polio virus was released into the local sewage system.
Genzyme has filed a patent application for a technology platform that will bridge the gap between upstream and downstream processing in continuous biomanufacturing.
Common environmentally practices for single-use systems must be adapted before industry “becomes too set in its ways,” says Greenpeace, despite biocontamination currently impeding recycling efforts.
Ampio Biopharmaceuticals will delay the release of Ampion trial data after discovering the drug was damaged by temperature fluctuations during shipment.
Second quarter sales of cryopreservation media grew 14% but BioLife Solutions says it expects revenues to skyrocket as clients’ biologics move out of the clinical stage..
As the fight over naming biosimilars continues in the US, the WHO has drafted its own system of biological qualifiers to ensure biosimilars remain unique from their biologic counterparts.
Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.
Interest in creating alternatives to Protein A has waned in light of more viable cost-saving opportunities in bioprocessing, such as single-use adoption, says Repligen.
Applied Genetic Technologies Corporation (AGTC), a developer of biologics for rare eye diseases, has agreed to let SAFC to manufacture gene therapies for clients using its HAVE platform.
A new UK “biologics facility of the future” (FoF) testing centre will let biopharma tech firms develop smaller-scale manufacturing systems for personalised medicine production according to the Centre for Process Innovation (CPI).
Protein A will keep its key role in therapeutic mAb production but next generation biotherapeutics will see Protein L become increasingly import says GE Healthcare.
A long dead cocker spaniel will play a key role in helping people avoid the flu this winter after a landmark approval from the US FDA for Novartis’ cell culture based vaccine plant.
Small biotechs should consider buying mothballed plants when scaling-up according to Protein Sciences, which says an ex-Pfizer facility was key to accelerating production of its vaccine Flublok.
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
Horizon, which supplies genomics research services, has bought cell-screening business CombinatoRx from Zalicus for £4.74m ($8m) and plans more acquisitions.
Bioprocessing instrument manufacturer Waters has reported a flat Q1, but management predicts new products and a delayed release of capital from large pharma will lead to growth in 2014.
Biopharma is ramping up the outsourcing of some of the easier tests while tasks such as downstream process development and QbD services are being outsourced less, according to a new survey.
A ‘spinning membrane’ technology could provide an automated solution to the manual problem of cell washing in both upstream and downstream processes says Fresenius Kabi.
Thermo Fisher has launched a pump technology designed for applications across the bioprocessing production line and usable with "all" bioprocessing tech.
Development of new anti-choloesterol drugs containing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibiting monoclonal antibodies could double Repligen Bioprocessing’s earning power, according to a Jefferies analyst.
Northwest Biotherapeutics, which is developing personalized immune therapies for brain cancer patients, has raised $32m to fund expansion of its manufacturing operations in Europe.
Adaptimmune has selected Biolife’s cryopreservation media for its genetically modified T-cell receptor (TCR) product citing its ability to retain viability and potency.
Novasep has reported a 14 percent growth in its biopharma business driven in part by demand for downstream manufacturing and its continuous chromatography systems.
Researchers are developing a cellulose filter paper they claim is at least as effective at removing viruses from biopharmaceutical production streams as currently available industrial systems.
Patheon brings fill/finish capabilities to DSM’s biomanufacturing services, President of Biopharma at the recently merged company DPx told Biopharma-Reporter.com in an exclusive interview.
Less H5N1 influenza vaccine than expected will be available in Japan this year after downstream processing problems at a plant being set up by Daiichi Sankyo.
Watson-Marlow Pumps Group (WMPG) has bought single-use connection technology developer Bio Pure Technology in a deal designed to bolster its biopharmaceutical manufacturing portfolio.
Outdated technology is one of the greatest challenges in creating next-generation biodrugs, says Jonathan Robinson, who is leading the development of a £38m ($63m) national biomanufacturing hub in the UK.
Downstream processing techs are harder to use and the focus of less innovation than systems employed upstream says the team developing the UK's new National Biologics Manufacturing Centre.
Cobra says it will no longer need to rely on third-parties for its biologics quality control tests after receiving an extension to its GMP certification at a Swedish facility.
